EE9900354A - Alzheimeri tõve ärahoidmise ja selle alguse edasilükkamise meetod ning selleks mõeldud kompositsioon - Google Patents

Alzheimeri tõve ärahoidmise ja selle alguse edasilükkamise meetod ning selleks mõeldud kompositsioon

Info

Publication number
EE9900354A
EE9900354A EEP199900354A EEP9900354A EE9900354A EE 9900354 A EE9900354 A EE 9900354A EE P199900354 A EEP199900354 A EE P199900354A EE P9900354 A EEP9900354 A EE P9900354A EE 9900354 A EE9900354 A EE 9900354A
Authority
EE
Estonia
Prior art keywords
alzheimer
delaying
onset
disease
preventing
Prior art date
Application number
EEP199900354A
Other languages
English (en)
Estonian (et)
Inventor
Novak Egon
Original Assignee
Forbes Medi-Tech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi-Tech Inc. filed Critical Forbes Medi-Tech Inc.
Publication of EE9900354A publication Critical patent/EE9900354A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP199900354A 1997-12-18 1998-12-18 Alzheimeri tõve ärahoidmise ja selle alguse edasilükkamise meetod ning selleks mõeldud kompositsioon EE9900354A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (fr) 1997-12-18 1998-12-18 Procede pour prevenir et retarder l'apparition de la maladie d'alzheimer, et composition utilisee a cet effet

Publications (1)

Publication Number Publication Date
EE9900354A true EE9900354A (et) 2000-02-15

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900354A EE9900354A (et) 1997-12-18 1998-12-18 Alzheimeri tõve ärahoidmise ja selle alguse edasilükkamise meetod ning selleks mõeldud kompositsioon

Country Status (18)

Country Link
US (1) US5985936A (fr)
EP (1) EP0967982A2 (fr)
CN (1) CN1252724A (fr)
AU (1) AU1656099A (fr)
BG (1) BG103740A (fr)
BR (1) BR9807577A (fr)
CA (1) CA2281710A1 (fr)
EE (1) EE9900354A (fr)
GE (1) GEP20022783B (fr)
HU (1) HUP0100737A3 (fr)
LT (1) LT4801B (fr)
LV (1) LV12438B (fr)
MD (1) MD1920F2 (fr)
NO (1) NO993979L (fr)
PL (1) PL335421A1 (fr)
RU (1) RU2173151C2 (fr)
SK (1) SK112999A3 (fr)
WO (1) WO1999032097A2 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
NZ518822A (en) * 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
KR20030005280A (ko) 2000-04-14 2003-01-17 마아즈, 인코오포레이티드 혈관의 건강을 개선하기 위한 조성물과 방법
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
WO2002064735A2 (fr) * 2001-02-12 2002-08-22 Akzo Nobel N.V. Methodes permettant d'ameliorer le traitement de depressions graves par genotypage visant a determiner le gene associe a l'apolipoproteine e4 et d'ameliorer la reponse therapeutique de personnes souffrant de depression grave et porteuses du gene associe a l'apolipoproteine e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
CA2517571C (fr) 2003-03-07 2011-07-05 Schering Corporation Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
CA2517573C (fr) * 2003-03-07 2011-12-06 Schering Corporation Composes d'azetidinone substitues, formulations et utilisations de ceux-ci pour traiter l'hypercholesterolemie
WO2004081003A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
CA2555367A1 (fr) * 2004-01-22 2005-08-11 Genaissance Pharmaceuticals, Inc. Marqueurs genetiques apoe associes a l'age de l'apparition de la maladie d'alzheimer
EP1814575A4 (fr) * 2004-11-24 2010-07-07 Neopro Labs Llc Methodes et compositions pour traiter des troubles
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
US20110053951A1 (en) * 2008-03-27 2011-03-03 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2010104375A1 (fr) 2009-03-12 2010-09-16 N.V. Nutricia Stigmastérol pour le traitement de la maladie d'alzheimer
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
WO2012149111A1 (fr) 2011-04-26 2012-11-01 The Regents Of The University Of California Procédés de promotion de réparation neuronale du snc par inhibition de lrp-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (fr) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Procédé d'augmentation de l'expression du gène bcl2
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
JP7370966B2 (ja) 2017-09-14 2023-10-30 フェニックス・バイオテクノロジー・インコーポレイテッド 神経学的状態を治療するための方法および改善された神経保護組成物
EP3842039A1 (fr) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Complément alimentaire comprenant des cannbinoïdes et des phytostérols pour la maladie d'alzheimer
EP4081198A1 (fr) 2019-12-24 2022-11-02 Folium Biosciences Europe B.V. Complément alimentaire pour la maladie d'alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
PL186441B1 (pl) * 1994-09-29 2004-01-30 Univ British Columbia Kompozycja obniżająca poziom cholesterolu, jej zastosowanie i zawierający ją produkt farmaceutyczny
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
ES2285772T3 (es) * 1997-05-15 2007-11-16 University Of Washington Composicion y metodos para tratar la enfermedad de alzheimer y otras amiloidosis.

Also Published As

Publication number Publication date
BR9807577A (pt) 2001-08-07
NO993979D0 (no) 1999-08-18
PL335421A1 (en) 2000-04-25
CN1252724A (zh) 2000-05-10
WO1999032097A3 (fr) 1999-09-02
CA2281710A1 (fr) 1999-07-01
WO1999032097A2 (fr) 1999-07-01
MD990262A (en) 2000-06-30
MD1920F2 (ro) 2002-05-31
NO993979L (no) 1999-10-13
LV12438A (en) 2000-03-20
AU1656099A (en) 1999-07-12
US5985936A (en) 1999-11-16
HUP0100737A3 (en) 2002-07-29
BG103740A (en) 2000-05-31
RU2173151C2 (ru) 2001-09-10
EP0967982A2 (fr) 2000-01-05
HUP0100737A2 (hu) 2001-09-28
SK112999A3 (en) 2001-11-06
LT4801B (lt) 2001-06-25
LV12438B (en) 2000-09-20
GEP20022783B (en) 2002-09-25
LT99114A (lt) 2001-01-25

Similar Documents

Publication Publication Date Title
EE9900354A (et) Alzheimeri tõve ärahoidmise ja selle alguse edasilükkamise meetod ning selleks mõeldud kompositsioon
NL300295I1 (nl) 3,3-Diarylpropylaminen, de toepassing en bereiding hiervan
ID18623A (id) Turunan-turunan naftiridin
ID17307A (id) Komposisi oral dan proses pembuatannya.
DE69715482D1 (de) Herstellung von 1,1,1,3,3-Pentachlorbutan und von 1,1,1,3,3-Pentafluorbutan
NO963032D0 (no) Oralt preparat
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
EE200000226A (et) 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
DK1140835T3 (da) 3,3-biarylpiperidin- og 2,2-biarylmorpholon-derivater
AU1743300A (en) Amino- and mercurio-substituted 4',5'-dihydropsoralens and therapeutical uses thereof
DE59912915D1 (de) Herstellung von 4,4'-Diketo-carotinoiden
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
EE200000099A (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
AU4560299A (en) Methods of diagnosing renal salt wasting syndrome and alzheimer's disease and methods of treating the same
DE69519913D1 (de) Dauerwellenzusammensetzung
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
DE69811651D1 (de) Enthaarungszusammensetzungen, die bereitung und die verwendung derselben
NO985535D0 (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
ID23156A (id) Turunan-turunan amidina, proses pembuatan komposisi dan penggunaannya
BR9709521A (pt) "3-Cianoaril-pirazóis"
EE9800085A (et) 3,5-difluoropüridiinid, nende valmistamismeetod, herbitsiidne kompositsioon ja nende kasutamine
DE69611546D1 (de) Herstellung von 2,6-dimethylnaphthalin
FI970269A0 (fi) 1,3-diolipohjaisten esterien seokset, menetelmä 1,3-diolipohjaisten esterien valmistamiseksi sekä esterien käyttö
NO306672B1 (no) N,N-dietyl-8,8-dipropyl-2-azaspiro[4,5]decan-2-propanamindimaleat, farmasöytisk blanding omfattende forbindelsen samt anvendelse derav
IT1320401B1 (it) Procedimento per la fabbricazione di componenti di un'ossatura ecomponenti di ossatura.